Argenx Se ADR (ARGX)

$787.94 -12.06 (-1.51%)
Market Cap 48.96B
Revenue (ttm) 2.25B
Net Income (ttm) 833.04M
EPS (ttm) N/A
PE Ratio 85.21
Forward PE 50.30
Profit Margin 36.99%
Debt to Equity Ratio 0.00
Volume 281,400
Avg Vol 403,818
Day's Range N/A - N/A
Shares Out 61.20M
Stochastic %K 85%
Beta 0.46
Analysts Strong Sell
Price Target $809.74

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren'...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 10 703 8441
Website: argenx.com
Address:
Laarderhoogtweg 25, Amsterdam, Netherlands
Travis1013
Travis1013 Oct. 5 at 10:52 PM
$ARGX https://chatgpt.com/s/t_68e0729422d48191bc93b606bee85c1c
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 11:30 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $800.00 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $49.63- $60.67 Scale out: $77.21-$99.27 Can Easily Capture: 60% ROI Blended DTE: 287 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Travis1013
Travis1013 Oct. 4 at 12:47 PM
$ARGX https://finance.yahoo.com/news/argenx-announces-extraordinary-general-meeting-200100050.html This is very interesting!!!! Thoughts from everyone??
3 · Reply
WAJeff
WAJeff Oct. 3 at 7:59 PM
$ARGX $803.74 ath
0 · Reply
moneybag888
moneybag888 Oct. 3 at 5:09 PM
$RIGL the next $ARGX $REGN #BeFirst
1 · Reply
moneybag888
moneybag888 Oct. 3 at 4:36 PM
$ARGX take some profits here … NFA still long 😎
1 · Reply
CDMO
CDMO Oct. 3 at 2:01 PM
$ARGX 800 to dump
1 · Reply
moneybag888
moneybag888 Oct. 3 at 11:57 AM
$ARGX $800 EOW 🎯
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 10:59 AM
$ARGX: Unusual Options Activity Alerted PUT flow observed 10x contracts at Strike price of $770 Exp on 02/20/2026 with Premium of $58K and showing BULLISH Sentiment
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 9:35 AM
$ARGX Really good write-up that perfectly summarizes ARGX's present situation. So if you want to bring your ARGX knowledge up to date or just discover ARGX, this is required reading. https://beyondspx.com/quote/ARGX/analysis/argenx-unlocking-autoimmunity-s-next-frontier-with-fcrn-leadership-and-a-deep-pipeline-nasdaq-argx
0 · Reply
Latest News on ARGX
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Oct 3, 2025, 4:01 PM EDT - 3 days ago

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

Sep 18, 2025, 9:00 AM EDT - 18 days ago

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

argenx SE - Special Call

Sep 16, 2025, 9:23 PM EDT - 20 days ago

argenx SE - Special Call

argenx: Bullish On This R&D Focused Biotech Stock

Sep 12, 2025, 4:16 AM EDT - 24 days ago

argenx: Bullish On This R&D Focused Biotech Stock

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:12 AM EDT - 4 weeks ago

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 4 weeks ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

BBH BMRN CYTK IBB XBI

argenx to Present at Upcoming Investor Conferences

Aug 28, 2025, 1:00 AM EDT - 5 weeks ago

argenx to Present at Upcoming Investor Conferences

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Aug 26, 2025, 1:35 PM EDT - 5 weeks ago

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Aug 25, 2025, 1:00 AM EDT - 6 weeks ago

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Aug 19, 2025, 1:00 AM EDT - 6 weeks ago

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Aug 12, 2025, 6:45 AM EDT - 7 weeks ago

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Aug 7, 2025, 9:35 PM EDT - 2 months ago

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

COO ELV HQY IDXX INSM ISRG RDNT

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 2 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 2 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN AZN BAX BIIB

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:22 PM EDT - 2 months ago

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 31, 2025, 1:00 AM EDT - 2 months ago

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

Jul 24, 2025, 1:00 AM EDT - 2 months ago

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Jun 30, 2025, 1:13 PM EDT - 3 months ago

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 20, 2025, 1:00 PM EDT - 3 months ago

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

Jun 10, 2025, 6:01 PM EDT - 4 months ago

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 1:00 AM EDT - 4 months ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025, 4:01 PM EDT - 4 months ago

argenx Announces Results of Annual General Meeting of Shareholders

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

May 9, 2025, 8:02 AM EDT - 5 months ago

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:16 PM EDT - 5 months ago

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 1:00 AM EDT - 5 months ago

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 1:00 AM EDT - 5 months ago

argenx to Present at BofA Securities 2025 Health Care Conference

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025, 1:00 AM EDT - 5 months ago

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 1:00 AM EDT - 5 months ago

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

Apr 11, 2025, 5:41 PM EDT - 6 months ago

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Apr 11, 2025, 4:01 PM EDT - 6 months ago

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025, 5:59 PM EDT - 6 months ago

US FDA approves syringe version of Argenx's immune disorder drug

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 5:47 PM EDT - 6 months ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Apr 8, 2025, 1:00 AM EDT - 6 months ago

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 6 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI CCL CEPU CF CROX CUK DECK

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Mar 7, 2025, 1:00 AM EST - 7 months ago

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 3:17 PM EST - 7 months ago

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27, 2025, 11:58 AM EST - 7 months ago

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Feb 27, 2025, 1:00 AM EST - 7 months ago

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 1:00 AM EST - 7 months ago

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Feb 20, 2025, 1:00 AM EST - 8 months ago

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

Jan 13, 2025, 1:00 AM EST - 9 months ago

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 1:00 AM EST - 9 months ago

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Dec 27, 2024, 1:00 AM EST - 10 months ago

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Nov 20, 2024, 1:00 AM EST - 11 months ago

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

Nov 19, 2024, 9:10 AM EST - 11 months ago

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Nov 11, 2024, 7:30 AM EST - 11 months ago

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Nov 11, 2024, 7:30 AM EST - 11 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ZLAB

argenx to Participate at Upcoming Investor Conferences

Nov 5, 2024, 1:00 AM EST - 11 months ago

argenx to Participate at Upcoming Investor Conferences

Travis1013
Travis1013 Oct. 5 at 10:52 PM
$ARGX https://chatgpt.com/s/t_68e0729422d48191bc93b606bee85c1c
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 11:30 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $800.00 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $49.63- $60.67 Scale out: $77.21-$99.27 Can Easily Capture: 60% ROI Blended DTE: 287 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Travis1013
Travis1013 Oct. 4 at 12:47 PM
$ARGX https://finance.yahoo.com/news/argenx-announces-extraordinary-general-meeting-200100050.html This is very interesting!!!! Thoughts from everyone??
3 · Reply
WAJeff
WAJeff Oct. 3 at 7:59 PM
$ARGX $803.74 ath
0 · Reply
moneybag888
moneybag888 Oct. 3 at 5:09 PM
$RIGL the next $ARGX $REGN #BeFirst
1 · Reply
moneybag888
moneybag888 Oct. 3 at 4:36 PM
$ARGX take some profits here … NFA still long 😎
1 · Reply
CDMO
CDMO Oct. 3 at 2:01 PM
$ARGX 800 to dump
1 · Reply
moneybag888
moneybag888 Oct. 3 at 11:57 AM
$ARGX $800 EOW 🎯
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 10:59 AM
$ARGX: Unusual Options Activity Alerted PUT flow observed 10x contracts at Strike price of $770 Exp on 02/20/2026 with Premium of $58K and showing BULLISH Sentiment
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 9:35 AM
$ARGX Really good write-up that perfectly summarizes ARGX's present situation. So if you want to bring your ARGX knowledge up to date or just discover ARGX, this is required reading. https://beyondspx.com/quote/ARGX/analysis/argenx-unlocking-autoimmunity-s-next-frontier-with-fcrn-leadership-and-a-deep-pipeline-nasdaq-argx
0 · Reply
moneybag888
moneybag888 Oct. 2 at 9:23 PM
$ARGX 🚀🚀🚀🚀 $800 EOW 🙏 $900 EOM 🙏
0 · Reply
SilverEagle
SilverEagle Oct. 2 at 3:30 PM
$ARGX or next month.
0 · Reply
WAJeff
WAJeff Oct. 2 at 2:35 PM
$ARGX $792.92 ath
1 · Reply
Funtoers
Funtoers Oct. 2 at 2:16 PM
$ARGX will we see $1000 this year?
1 · Reply
moneybag888
moneybag888 Oct. 2 at 12:16 PM
$ARGX $800+ 🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
moneybag888
moneybag888 Oct. 1 at 9:11 PM
$TMO $ARGX 🚀🚀🚀🚀
0 · Reply
moneybag888
moneybag888 Oct. 1 at 7:26 PM
$ARGX 🚀🚀🚀🚀
0 · Reply
WAJeff
WAJeff Oct. 1 at 5:07 PM
$ARGX $786.20 ath
1 · Reply
anachartanalyst
anachartanalyst Oct. 1 at 5:02 PM
$ARGX https://anachart.com/wp-content/uploads/ana_temp/1759338130_soc-img.jpg
0 · Reply
ChessGM
ChessGM Oct. 1 at 3:51 PM
$ARGX Argenx's Broader Pipeline Value Underappreciated, Morgan Stanley Says
0 · Reply
WAJeff
WAJeff Oct. 1 at 3:21 PM
$ARGX 66 cents from another ath today
2 · Reply
moneybag888
moneybag888 Oct. 1 at 2:06 PM
$ARGX #BeFirst #Believe 🚀🚀🚀😎
0 · Reply